ClinicalTrials.gg
CompletedNCT05320393Updated Sep 4, 2024Results posted

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

A Phase 2 interventional study of PrabotulinumtoxinA-Xvfs and OnabotulinumtoxinA in Glabellar Frown Lines, sponsored by Evolus, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Evolus, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.

Read the detailed description

This is a multicenter, prospective, randomized, double-blind, active-controlled, single-treatment, increasing dose design. Up to one hundred and fifty subjects will be randomized 1:1:1, to either 20 Units onabotulinumtoxinA (Botox® Cosmetic), 20 Units prabotulinumtoxinA-xvfs (Jeuveau®), or 40 Units prabotulinumtoxinA-xvfs (Jeuveau®).

02

Conditions studied

  • Glabellar Frown Lines

Keywords

  • Botulinum toxin type A
03

In context

Lead sponsor

Evolus, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient, male or female of any race, 18 years of age or older.
  • Female subjects of must have a negative urine pregnancy test during Visits 1 (Screening) and Visit 2 (if applicable) and practice a reliable method of for the duration of the study.
  • Moderate to severe glabellar lines (i.e., score of 2 or 3) on maximum frown as assessed by the investigator using the Glabellar Line Scale (GLS).
  • Subject has moderate to severe glabellar lines (i.e., score of 2 or 3) at maximum frown as assessed by the subject using the GLS.
  • Able to follow study instructions and likely to complete all required visits.
  • Sign the Institutional Review Board (IRB) -approved Form (ICF) prior to any study-related procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, breast-feeding, or of and not practicing reliable .
  • Known or previous allergic reaction to any constituent of the Product (IP) or control.
  • Any active infection in the area of the injection sites.
  • Inability to substantially lessen glabellar frown lines even by physically spreading them apart.
  • Marked facial asymmetry (Investigator discretion).
  • Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis.
  • History of facial nerve palsy.
  • Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (Investigator discretion).
  • Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis).
  • Previous treatment with botulinum toxin of any serotype above the level of the lateral canthus within the last 6 months.
  • Planned treatment with botulinum toxin of any serotype below the level of the lateral canthus during the study period.
  • Previous treatment with any facial aesthetic procedure (e.g., injection with biodegradable fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months.
  • Previous insertion of permanent material in the glabellar area.
  • Any previous energy based or cryotherapy-based treatment of facial muscles superior to the lateral canthus.
  • Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (can continue with their usual skin care routine).
  • Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles, or a combination of these, or scars in the glabellar area and the surrounding areas (including eyebrow).
  • Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  • Evidence of recent alcohol or drug abuse (Investigator discretion).
  • History of poor cooperation or unreliability.
  • Planning to move out of the area prior to study completion.
  • Subjects who are investigational site staff members or family members of such employees.
  • Exposure to any other investigational drug/device within 30 days prior to Visit 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Study Drug

    40U of PrabotulinumtoxinA-xvfs

    Drug: PrabotulinumtoxinA-Xvfs

  • Active comparator
    OnabotulinumtoxinA

    20U of OnabotulinumtoxinA

    Drug: OnabotulinumtoxinA

  • Active comparator
    PrabotulinumtoxinA-xvfs

    20U of PrabotulinumtoxinA-xvfs

    Drug: PrabotulinumtoxinA-Xvfs

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of Effect Described by Kaplan-Meier Analysis

    Effectiveness of prabotulinumtoxinA 40 Units compared to prabotulinumtoxinA 20 Units will be assessed for each subject based on the number of days from baseline to the day that the Glabellar Line Scale (GLS) severity, by Investigator Assessment, returns to the baseline value. The treatment will be considered to remain effective for the amount of time during which the GLS severity at maximum frown has not returned to baseline severity.

    Time frame: Duration of effect for each subject will be based on number of days from baseline to the day that Glabellar Line Scale severity (Investigator Assessment) returns to baseline value, assessed every 30 days up to 365 days.

07

Results

Posted Sep 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneStudy DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfs
Started515053
Completed494847
Not completed226
Withdrew: Withdrawal by subject102
Withdrew: Lost to follow-up121
Withdrew: Moved; too much driving002
Withdrew: Did not receive treatment001

Outcome measures

PrimaryDuration of Effect Described by Kaplan-Meier Analysis

Effectiveness of prabotulinumtoxinA 40 Units compared to prabotulinumtoxinA 20 Units will be assessed for each subject based on the number of days from baseline to the day that the Glabellar Line Scale (GLS) severity, by Investigator Assessment, returns to the baseline value. The treatment will be considered to remain effective for the amount of time during which the GLS severity at maximum frown has not returned to baseline severity.

Time frame:
Duration of effect for each subject will be based on number of days from baseline to the day that Glabellar Line Scale severity (Investigator Assessment) returns to baseline value, assessed every 30 days up to 365 days.
Reported as:
Median · Days
Duration of Effect Described by Kaplan-Meier Analysis
DaysStudy DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfs
Duration of Effect Described by Kaplan-Meier Analysis183 (153 to 211)148 (121 to 174)149 (130 to 174)
Statistical analysis
  • Study Drug vs OnabotulinumtoxinA vs PrabotulinumtoxinA-xvfs · Log Rank · p = 0.0109

Adverse events

Collected over Adverse event data were collected over a period of up 12 months post treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Drug0/51 (0%)0/51 (0%)2/51 (3.9%)
OnabotulinumtoxinA0/50 (0%)0/50 (0%)5/50 (10%)
PrabotulinumtoxinA-xvfs0/53 (0%)0/53 (0%)3/52 (5.8%)
Most frequent other events
Most frequent other events
EventStudy DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfs
COVID-19Infections and infestations0/513/500/52
HeadacheNervous system disorders2/512/503/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Mean46.8 ± 11.347.0 ± 11.146.8 ± 12.947 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Female484750145
Male3339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Hispanic or Latino20161551
Not Hispanic or Latino313437102
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American3238
White484749144
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
United States515053154
Participant Has a Prior history of botulinum toxin use
Participant Has a Prior history of botulinum toxin use(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Count of participants26261971
Glabellar Line Score of Moderate at Maximum Frown by Investigator Assessment
Glabellar Line Score of Moderate at Maximum Frown by Investigator Assessment(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Count of participants15141847
Glabellar Line Score of Moderate at Maximum Frown by Subject Assessment
Glabellar Line Score of Moderate at Maximum Frown by Subject Assessment(Participants)Study DrugOnabotulinumtoxinAPrabotulinumtoxinA-xvfsTotal
Count of participants1171331

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Aesthetic Eyelid Plastic Surgery
    Boca Raton, Florida 33431, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2023, 13 months.

Results were first posted in Sep 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Apr 11, 2022
StartActual
Mar 30, 2022
Primary completionActual
May 22, 2023
CompletionActual
May 22, 2023
Results first posted
Sep 4, 2024
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05320393
Lead sponsor
Evolus, Inc.
Collaborators
ethica Clinical Research Inc.
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Mar 30, 2022
Primary completion
May 22, 2023
Completion
May 22, 2023
Results posted
Sep 4, 2024
Last update
Sep 4, 2024

Study contacts

Rui Avelar, MD
study director · Evolus, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion